Market Place
Sourcing Support
Kiromic Reports 10-Month PFS For Patient 4 In Deltacel-01 Trial
18 Feb 2025 //
BUSINESSWIRE
Kiromic Resolves Previously Disclosed SEC Investigation
03 Dec 2024 //
BUSINESSWIRE
Kiromic Reports Results From Deltacel-01 Enrolled Patients
08 Oct 2024 //
BUSINESSWIRE
Kiromic BioPharma Activates University Of Arizona Cancer Site
19 Sep 2024 //
BUSINESSWIRE
Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase
19 Sep 2024 //
BUSINESSWIRE
Kiromic BioPharma’s Deltacel Receives FDA Fast Track Designation
14 Aug 2024 //
BUSINESSWIRE
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
09 Aug 2024 //
BUSINESSWIRE
Kiromic Reports 20% Tumor Reduction In First Deltacel-01 Patient
01 Aug 2024 //
PRESS RELEASE
Kiromic BioPharma Advances Deltacel-01 Trial To Expansion Phase
18 Jul 2024 //
BUSINESSWIRE
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
20 Jun 2024 //
BUSINESSWIRE
Kiromic: 6-Month Deltacel-01 Results From First Patient
06 Jun 2024 //
BUSINESSWIRE
Kiromic Reports 6-Week Favorable Data From Deltacel-01 Trial Patient 4
29 May 2024 //
BUSINESSWIRE
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
20 May 2024 //
BUSINESSWIRE
Kiromic Reports Consistent Deltacel-01 Trial Data
24 Apr 2024 //
BUSINESSWIRE
Kiromic Reports Favorable from Third Patient in Deltacel-01 Trial
02 Apr 2024 //
BUSINESSWIRE
Early Efficacy Results Show Primary Lung Tumor Kiromic BioPharma’s Deltacel-01
19 Mar 2024 //
BUSINESSWIRE
Kiromic Bio to Present at the OTC Markets’ Virtual Life Science Investor Forum
28 Feb 2024 //
BUSINESSWIRE
Kiromic BioPharma’s Deltacel-01 Trial Indicate Tumor Reduction at Two Months
14 Feb 2024 //
BUSINESSWIRE
Kiromic Reports Favorable Results from First Patient in Deltacel-01 Phase 1
29 Jan 2024 //
BUSINESSWIRE
Kiromic Reports Favorable Safety and Tolerability Data from Deltacel-01 Trial
05 Jan 2024 //
BUSINESSWIRE
Kiromic Bio Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel
14 Dec 2023 //
BUSINESSWIRE
Kiromic BioPharma Announces Uplisting to OTCQB Market
16 Nov 2023 //
BUSINESSWIRE
Kiromic Announces Deltacel™ Phase 1 Trial Enters Patient Recruitment Phase
09 Nov 2023 //
BUSINESSWIRE
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
23 Oct 2023 //
BUSINESSWIRE
Kiromic Common Stock to Begin Trading on the OTC Pink Sheets on September 14
13 Sep 2023 //
BUSINESSWIRE
Kiromic BioPharma Welcomes Two New Directors to its Board
24 Jul 2023 //
BUSINESSWIRE
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Ph 1 Trial
01 May 2023 //
BUSINESSWIRE
Kiromic Submits IND for PI Trial with Deltacel for Non-Small Cell Lung Cancer
03 Apr 2023 //
BUSINESSWIRE
Kiromic BioPharma Announces Reverse Stock Split
10 Mar 2023 //
BUSINESSWIRE
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
28 Feb 2023 //
BUSINESSWIRE
Proxy Advisory Firms Recommend Kiromic Stockholders Vote “FOR” Proxy Proposals
23 Feb 2023 //
BUSINESSWIRE
Kiromic BioPharma CEO Issues Letter to Stockholders
16 Feb 2023 //
BUSINESSWIRE
Kiromic BioPharma Arranges Up to $10 Million Financing
27 Oct 2022 //
BUSINESSWIRE
Kiromic Announces FDA Feedback from Type B Pre-IND Meeting
06 Oct 2022 //
BUSINESSWIRE
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
12 Jul 2022 //
BUSINESSWIRE
Kiromic Bio Achieves Milestone with Completion of Expanded cGMP Mfg Facility
07 Jul 2022 //
BUSINESSWIRE
Kiromic BioPharma Pipeline to Prioritize Gamma Delta T-cell Product Candidate
21 Jun 2022 //
BUSINESSWIRE
Kiromic BioPharma Reports First Quarter 2022 Financial Results
13 May 2022 //
BUSINESSWIRE
Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel
11 May 2022 //
BUSINESSWIRE
Kiromic BioPharma Announces Availability of Current Corporate Presentation
11 Apr 2022 //
BUSINESSWIRE
Kiromic BioPharma Reports Q4 and Full-Year 2021 Financial Results
08 Apr 2022 //
BUSINESSWIRE
Kiromic Biopharma Announces Filing of Form 12b-25
01 Apr 2022 //
BUSINESSWIRE
Kiromic BioPharma Reports Third Quarter 2021 Financial Results
11 Mar 2022 //
BUSINESSWIRE
Kiromic BioPharma Announces Changes in Management, Board of Directors
03 Feb 2022 //
BUSINESSWIRE
Kiromic BioPharma Announces Receipt of Notice from Nasdaq
24 Nov 2021 //
BUSINESSWIRE
Kiromic , Now Clinical Stage, Reports Significant Progression Free Survival
25 Oct 2021 //
BUSINESSWIRE
Kiromic Collaborates with Gemelli for Analysis of Allogeneic CAR-T Trial
11 Oct 2021 //
BIOSPACE
Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Highlights
13 Aug 2021 //
BUSINESSWIRE
Kiromic Announces the Acquisition of InSilico Solutions
26 Jul 2021 //
BUSINESSWIRE
Kiromic Provides Update on IND Filings on its Allogeneic CAR-T for Solid Tumors
16 Jul 2021 //
BUSINESS WIRE
Kiromic BioPharma, Inc. Announces Closing of Public Offering
02 Jul 2021 //
BUSINESSWIRE
Kiromic BioPharma, Inc. Announces Pricing of Public Offering
29 Jun 2021 //
BUSINESSWIRE
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility
07 Jun 2021 //
BUSINESSWIRE
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf
24 May 2021 //
BUSINESSWIRE
Kiromic Announces FDA IND Submission Forty-Five Days before the end
17 May 2021 //
BUSINESSWIRE
Kiromic Announces Posters Presented at AACR 2021
03 May 2021 //
BUSINESSWIRE
Kiromic Announces License Agreement With Longwood University for chPD1
26 Jan 2021 //
BUSINESSWIRE
Kiromic Biopharma seeks European patents for Chimeric PD-1 (chPD1) target
05 Jan 2021 //
PHARMABIZ
